All In Biotech

Drug Trial Radar · NCT04998604

EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma Patients

Last checked: Nov 20, 2026Latest source record: Oct 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

360

Actual

Start

Sep 27, 2021

Primary completion

Oct 16, 2024

Study completion Dec 27, 2024

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Aug 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective -To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smell Secondary Objectives * To evaluate the efficacy of dupilumab in improving chronic rhinosinusitis with nasal polyps (CRSwNP) symptoms at Week 24 compared to omalizumab * To evaluate the efficacy of dupilumab in improving CRSwNP total symptom score (TSS) at Week 24 compared to omalizumab * To evaluate the effect of dupilumab on health related quality of life (HRQoL) at week 24 compared to omalizumab * To evaluate the efficacy of dupilumab in improving nasal peak inspiratory flow at Week 24 compared to omalizumab * To evaluate the effect of dupilumab on CRSwNP overall disease severity at Week 24 compared to omalizumab * To evaluate the safety of dupilumab and omalizumab

Conditions

  • Chronic Rhinosinusitis With Nasal Polyps
  • Asthma

Interventions

  • DupilumabDrug

    solution for injection subcutaneous

  • OmalizumabDrug

    solution for injection subcutaneous

  • PlaceboDrug

    solution for injection subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 24 in Nasal Polyp ScoreTime frame: Baseline (Day 1) and Week 24
  2. Change From Baseline to Week 24 in University of Pennsylvania Smell Identification TestTime frame: Baseline (Day 1) and Week 24

Locations

87 sites in 17 countries. Site status is shown where the registry gives one.

  • Cedars Sinai Medical Center Site Number : 8400026

    Los Angeles, California

  • Asthma Allergy & Immunology Clinical Research Unit Site Number : 8400027

    Tampa, Florida

  • Northwestern University Site Number : 8400001

    Chicago, Illinois

  • University of Illinois

    Chicago, Illinois

  • Advanced ENT and Allergy Site Number : 8400013

    Louisville, Kentucky

  • University of Missouri Health Care - University Hospital Site Number : 8400016

    Columbia, Missouri

  • Northwell Health Site Number : 8400044

    Great Neck, New York

  • University of Rochester Site Number : 8400015

    Rochester, New York

  • Cleveland Clinic Foundation Site Number : 8400029

    Cleveland, Ohio

  • Optimed Research, LTD Site Number : 8400014

    Columbus, Ohio

  • Allergy, Asthma and Clinical Research Center Site Number : 8400037

    Oklahoma City, Oklahoma

  • Essential Medical Research, LLC Site Number : 8400024

    Tulsa, Oklahoma

  • Oregon Health & Science University Site Number : 8400031

    Portland, Oregon

  • University of Texas Health Science Center- Site Number : 8400019

    Houston, Texas

  • Chryaslis Clinical Research Site Number : 8400017

    St. George, Utah

  • Eastern Virginia Medical School Site Number : 8400010

    Norfolk, Virginia

  • Investigational Site Number : 0560001

    Ghent, Belgium

  • Investigational Site Number : 0560002

    Leuven, Belgium

  • Investigational Site Number : 0560003

    Woluwe-Saint-Lambert, Belgium

  • Investigational Site Number : 1240003

    Québec, Canada

  • Investigational Site Number : 1240004

    London, Ontario, Canada

  • Investigational Site Number : 1240002

    Montreal, Quebec, Canada

  • Investigational Site Number : 2030007

    Benešov, Czechia

  • Investigational Site Number : 2030001

    Hradec Králové, Czechia

  • Investigational Site Number : 2030003

    Ostrava - Poruba, Czechia

  • Investigational Site Number : 2030002

    Pardubice, Czechia

  • Investigational Site Number : 2030012

    Pilsen, Czechia

  • Investigational Site Number : 2030010

    Prague, Czechia

  • Investigational Site Number : 2030006

    Prague, Czechia

  • Investigational Site Number : 2030008

    Prague, Czechia

  • Investigational Site Number : 2030004

    Praha 5 - Motole, Czechia

  • Investigational Site Number : 2080003

    Aarhus, Denmark

  • Investigational Site Number : 2080001

    Copenhagen, Denmark

  • Investigational Site Number : 2460003

    Helsinki, Finland

  • Investigational Site Number : 2460002

    Tampere, Finland

  • Investigational Site Number : 2500009

    Créteil, France

  • Investigational Site Number : 2500006

    La Roche-sur-Yon, France

  • Investigational Site Number : 2500008

    Le Kremlin-Bicêtre, France

  • Investigational Site Number : 2500002

    Lille, France

  • Investigational Site Number : 2500004

    Marseille, France

Showing 40 of 87 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.